At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Jun 16, 2026 at 07:01 ET
Invivyd announced completion of enrollment in its Phase 3 LIBERTY trial comparing VYD2311 (monoclonal antibody) against an mRNA COVID vaccine, with topline data expected in Q3 2026. The trial is part of the broader REVOLUTION program aiming to position VYD2311 as an alternative to vaccines. This is a clinical milestone with no efficacy or safety data yet, so the immediate stock impact is limited.
- Phase 3 LIBERTY trial enrollment complete; ~210 participants randomized, double-blind.
- Primary endpoint: safety/tolerability of VYD2311 vs mRNA COVID vaccine through Day 6.
- Topline data expected in Q3 2026, potentially alongside DECLARATION pivotal trial data.
- VYD2311 is engineered from same backbone as pemivibart (EUA for immunocompromised PrEP) and adintrevimab.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access